Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Inflammatory Bowel Diseases 2Crohn Disease 2

Interventions

Certolizumab Pegol 5Infliximab 4Adalimumab 3Nivolumab 2MEDI2070 2vedolizumab 1secukinumab 1golimumab 1cabozantinib 1Vitamin E 1Vaccines 1Ustekinumab 1Sutures 1Surgical Instruments 1Specimen Handling 1Soybean Oil 1Saline Solution 1Ringer's Lactate 1Pneumococcal Vaccines 1Platinum Compounds 1Photoplethysmography 1Papillomavirus Vaccines 1Methoxsalen 1Medical Marijuana 1Lysine Acetyltransferase 5 1Iron-Dextran Complex 1Ipilimumab 1Indigo Carmine 1Hydroxyethyl Starch Derivatives 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Crohn Disease × MEDI2070 × Clear all
NCT01714726 2021-05-26

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

AstraZeneca

Phase 2 Completed
121 enrolled 22 charts

Crohn Disease, Inflammatory Bowel Diseases

NCT02574637 2021-05-26

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

AstraZeneca

Phase 2 Terminated
29 enrolled 25 charts

Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡